From October 16 to 18, 2026, the 5th West Lake Gynecologic Oncology Conference, the 2026 Academic Annual Meeting of the Gynecologic Oncology Committee of the Zhejiang Anti-Cancer Association, and the 2026 Academic Conference of the Cervical Cancer Integrated Prevention and Screening Committee of the Chinese Anti-Cancer Association were held in Hangzhou, China. The events were organized by the Zhejiang Anti-Cancer Association and undertaken by Zhejiang Cancer Hospital and the Cervical Cancer Integrated Prevention and Screening Committee of the Chinese Anti-Cancer Association. The meetings focused on basic and clinical research in gynecologic oncology and advances in surgical techniques, with discussions addressing key challenges in precision and individualized treatment.

Hepatocellular carcinoma (HCC) complicated by portal vein tumor thrombus (PVTT) is associated with a very poor prognosis, limited treatment options, and substantial clinical challenges. Immunotherapy combined with targeted therapy has become an important first-line treatment approach for unresectable HCC. Although the triplet strategy of hepatic arterial infusion chemotherapy (HAIC) combined with immunotherapy and targeted therapy has demonstrated promising antitumor activity in small phase II studies, large-scale real-world evidence confirming its survival benefits has been lacking.

From September 16 to 19, 2026, the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), jointly organized by CSCO and the Beijing Xisike Clinical Oncology Research Foundation, was held in Jinan, Shandong Province, China. The meeting brought together oncology experts from China and around the world to address real-world clinical challenges, share cutting-edge advances, and engage in discussions on novel drug development and optimization of diagnostic and treatment strategies, fostering in-depth academic exchange between the international oncology community.

The 29th Chinese Society of Clinical Oncology (CSCO) Academic Annual Meeting was held in Jinan from September 16 to 19, 2026. Under the theme “Upholding Standards and Advancing Digital and Intelligent Innovation,” the meeting showcased China's achievements in oncology innovation, reflecting the country's transition from following global advances to keeping pace with—and increasingly leading—the field. In the treatment of RAS wild-type metastatic colorectal cancer (mCRC), the introduction of China's domestically developed, fully human anti-EGFR antibody panitumumab N01 is significantly reshaping the anti-EGFR treatment landscape. During the meeting, Professor Yanhong Deng of the Sixth Affiliated Hospital of Sun Yat-sen University spoke with Oncology Frontier about the evolution of first-line treatment for advanced RAS wild-type colorectal cancer, the clinical value of panitumumab N01, and the future of China's innovative medicines.

The 29th CSCO Academic Annual Meeting, jointly organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was grandly opened in Jinan, Shandong Province, from September 17 to 19, 2026. With the theme “Upholding Standards and Advancing Digital and Intelligent Innovation,” the annual meeting continued CSCO's longstanding mission of bringing together renowned oncology experts and scholars from around the world to share cutting-edge research findings and clinical experience. The meeting is expected to further advance cancer diagnosis and treatment in China and worldwide.

Clear cell sarcoma is an extremely rare subtype of soft tissue sarcoma. Owing to its low incidence and limited clinical understanding, there has long been no established standard treatment, and therapeutic options remain limited. The c-MET pathway plays a critical role in the development and progression of clear cell sarcoma. However, previous studies of MET inhibitors have yielded disappointing results, highlighting the urgent need for better treatment strategies and more precise methods of identifying patients likely to benefit.

The 2026 CSCO Academic Annual Meeting was held in Jinan from September 16 to 19, bringing together oncology experts from China and around the world. On this occasion, Oncology Frontier invited Professor Yi-Long Wu of Guangdong Provincial People's Hospital to speak with Professor Everett Vokes, Chair of the Department of Medicine at the University of Chicago and former President of the American Society of Clinical Oncology (ASCO). Their discussion explored the biological characteristics of MET-amplified non-small cell lung cancer (NSCLC), the current diagnostic and treatment landscape in China and the United States, and future directions for international collaboration.

On the morning of September 17, 2026, the plenary session of the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) grandly opened at Shandong Hall, Shandong Building, in Jinan. Chaired by Professor Zefei Jiang, President-Elect of CSCO, the session featured Professor Shukui Qin, Chair of the CSCO Steering Committee, announcing the recipients of the society's awards. The honors showcased the year's achievements in original research, standardized cancer care, and the development of emerging talent in Chinese clinical oncology.

RET gene fusions are key oncogenic drivers in non-small cell lung cancer (NSCLC). Although detected in only approximately 1%–2% of patients, these alterations have a well-established role in tumorigenesis and represent an important therapeutic target in advanced lung cancer. In recent years, the introduction of highly selective RET inhibitors has substantially improved outcomes for patients with this molecular subtype. However, challenges remain in clinical practice, including safety management, acquired resistance, and intracranial efficacy.

The 2026 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), themed “Upholding Standards and Advancing Digital and Intelligent Innovation,” brought together leading oncology experts from China and abroad in Jinan. With China taking the lead and the global community participating, the meeting showcased the latest achievements and innovative momentum in Chinese clinical oncology. In an exclusive interview with Oncology Frontier, Professor Jinming Yu, President of CSCO and Academician of the Chinese Academy of Engineering, provided an in-depth interpretation of the theme's significance. He emphasized that adherence to standardized clinical practice is the foundation of high-quality development in cancer diagnosis and treatment in China, while digital and intelligent innovation serves as the core driver of further improvements in quality and care. From clarifying the innovative value of biosimilars to charting a path for Chinese innovative medicines to move beyond domestic substitution and compete globally, progress requires addressing current clinical needs while taking a long-term view of the development of oncology as a discipline.